9.3 Neonatal Hypoglycemia, Electrolyte Derangements & Hyperbilirubinemia

Neonatal Hypoglycemia, Electrolyte Derangements & Hyperbilirubinemia

Metabolic homeostasis in the neonate is uniquely precarious. During the immediate post-birth transition, an infant must shift from continuous transplacental nutrient delivery to autonomous endocrine regulation, gluconeogenesis, and independent electrolyte filtration. Critical illness, asphyxia, prematurity, or maternal metabolic disorders rapidly overwhelm these transitional mechanisms. Failure to swiftly identify and correct neonatal hypoglycemia, severe electrolyte disturbances, and hyperbilirubinemia results in permanent neurodevelopmental disability, cardiac arrest, or death during transport.

---

Neonatal Hypoglycemia: Thresholds, High-Risk Groups & GIR Calculations

The neonatal brain relies almost exclusively on continuous glucose oxidation for cerebral metabolic energy. Because ketone body production and glycogenolysis are limited in high-risk newborns, sustained or recurrent neuroglycopenia precipitates cerebral edema, parietal-occipital cortical necrosis, and long-term cognitive and visual impairment.

Operational Definitions & Treatment Thresholds

Guidance differs by source and hour of life:

• AAP (2011), at-risk late preterm and term infants: A symptomatic infant with glucose below 40 mg/dL receives IV dextrose. For asymptomatic infants, the AAP algorithm uses feeding and rechecks, with IV dextrose if glucose stays below about 25 mg/dL in the first 4 hours or below about 35 mg/dL at 4–24 hours; the pre-feed goal is at least 45 mg/dL.
• Pediatric Endocrine Society (2015): Keep glucose above 50 mg/dL in the first 48 hours and above 60 mg/dL after 48 hours (above 70 mg/dL when a persistent hypoglycemia disorder such as hyperinsulinism is suspected).
• In transport: A sick infant who is NPO needs IV dextrose. A commonly used steady-state target during stabilization is about 60–100 mg/dL.

High-Risk Neonatal Populations

1. Hyperinsulinemic States: Infants of Diabetic Mothers (IDM) and Large-for-Gestational-Age (LGA) infants. Chronic maternal hyperglycemia induces fetal pancreatic islet beta-cell hyperplasia and excessive fetal insulin production. At birth, maternal glucose abruptly ceases upon cord clamping, but hyperinsulinemia persists, driving glucose into muscle and fat while shutting down gluconeogenesis.
2. Inadequate Glycogen & Fat Stores: Premature infants ($<37$ weeks) and Small-for-Gestational-Age (SGA) / Intrauterine Growth Restriction (IUGR) infants lack late-trimester hepatic glycogen deposition and brown adipose tissue.
3. Increased Metabolic Utilization: Asphyxiated neonates (HIE), septic infants, hypothermic infants, and those in acute respiratory distress shift to inefficient anaerobic glycolysis (yielding only 2 ATP per glucose molecule compared to 36–38 ATP under aerobic conditions), exhausting glucose stores at an exponential rate.

Emergency Dextrose Therapy & The GIR Formula

• Acute Symptomatic Mini-Bolus: Administer 10% Dextrose in Water (D10W) at 2 mL/kg (equivalent to $200 \text{ mg/kg}$ or $0.2 \text{ g/kg}$) as a slow intravenous push over 5 minutes.
  • Critical Safety Mandate: Never administer concentrated dextrose (D25W or D50W) to a neonate. Hypertonic dextrose causes severe rebound hyperinsulinemia, hyperosmolality, and endothelial sloughing.
• Continuous Maintenance Infusion: Follow the mini-bolus immediately with a continuous dextrose infusion titrated to a physiological Glucose Infusion Rate (GIR).

$$\text{GIR } (\text{mg/kg/min}) = \frac{\% \text{ Dextrose} \times \text{Hourly IV Rate } (\text{mL/hr})}{\text{Patient Weight } (\text{kg}) \times 6}$$ $$\text{GIR } (\text{mg/kg/min}) = \frac{\% \text{ Dextrose} \times \text{Daily IV Volume } (\text{mL/kg/day})}{144}$$

• Clinical Application: Normal hepatic glucose production in healthy term infants is 4 to 6 mg/kg/min. High-risk infants, IDMs, and SGA neonates often require initial GIRs of 6 to 8 mg/kg/min, titrating upward in increments of 1 to 2 mg/kg/min up to 12 to 15+ mg/kg/min for refractory hyperinsulinism.
• Vascular Delivery Limits: The maximum dextrose concentration that can be safely infused through a peripheral intravenous catheter is 12.5% (D12.5W). Concentrations $>12.5\%$ (e.g., D15W, D20W) have high osmolarity ($>900 \text{ mOsm/L}$) that rapidly induces chemical phlebitis, vascular sclerosis, and full-thickness skin necrosis if extravasated. Central venous access (Umbilical Venous Catheter [UVC] or PICC) is mandatory for concentrations exceeding D12.5W.

---

Acute Electrolyte Derangements: Calcium, Sodium & Potassium

1. Neonatal Hypocalcemia

• Definitions: Ionized calcium ($iCa$) $< 1.0 \text{ to } 1.1 \text{ mmol/L}$ ($< 4.0 \text{ to } 4.4 \text{ mg/dL}$) or total serum calcium $< 7.0 \text{ to } 8.0 \text{ mg/dL}$ in term infants ($< 6.5 \text{ to } 7.0 \text{ mg/dL}$ in preterms).
• Pathophysiology: Placental calcium transfer ceases at delivery. Early hypocalcemia ($<72$ hours) occurs in prematurity, asphyxia (calcium deposition in damaged tissues and hyperphosphatemia), and IDM (maternal hypomagnesemia suppresses fetal parathyroid hormone).
• Clinical Manifestations: Neuromuscular excitability (jitteriness, high-pitched cry, hyperreflexia), prolonged QTc interval on EKG ($>0.42\text{--}0.44 \text{ s}$), stridor/laryngospasm, myocardial dysfunction with hypotension, and seizures refractory to phenobarbital.
• Emergency Treatment: 10% Calcium Gluconate at 1 to 2 mL/kg (100 to 200 mg/kg) diluted 1:1 with sterile water or normal saline, infused slowly IV over 10 to 30 minutes.
• Transport Mandates: Continuous cardiac rhythm monitoring is mandatory during infusion. Rapid bolusing triggers acute sinus bradycardia, sinus arrest, or fatal ventricular arrhythmias. Stop infusion immediately if heart rate drops. Ensure absolute line patency; extravasation causes severe subcutaneous calcinosis and sloughing. Never administer calcium gluconate through the same line as sodium bicarbonate, as it precipitates into insoluble calcium carbonate chalk.

2. Dysnatremias: Hyponatremia vs. Hypernatremia

• Hyponatremia ($Na^+ < 135 \text{ mEq/L}$; Critical $< 120-125 \text{ mEq/L}$): Caused by excessive free-water administration, SIADH (post-asphyxia or CNS infection), or salt-wasting renal disease. Severe acute hyponatremia causes cerebral edema, encephalopathy, and intractable seizures.
  • Treatment of Symptomatic Seizures: Administer 3% Hypertonic Saline at 3 to 5 mL/kg IV slowly over 15 to 30 minutes to rapidly elevate serum sodium by 3 to 5 mEq/L, aborting cerebral herniation.
• Hypernatremia ($Na^+ > 145-150 \text{ mEq/L}$): Caused by severe dehydration, inadequate breast milk intake, or excessive transepidermal evaporative water loss in ELBW infants under radiant warmers. Rapid reduction of hypernatremia leads to water rushing into hyperosmolar brain cells, causing acute brain swelling, herniation, and death. The rate of serum sodium reduction must strictly not exceed 0.5 mEq/L/hr (maximum 10 to 12 mEq/L per 24 hours).

3. Hyperkalemia

• Definitions: Serum potassium $>6.0 \text{ mEq/L}$ in term infants or $>6.5 \text{ mEq/L}$ in preterm infants. Always rule out pseudohyperkalemia caused by heelstick hemolysis.
• EKG Progression Ladder:

  Normal EKG ──> Tall, peaked, tented T waves (narrow base)
             ──> Prolongation of PR interval & flattening of P waves
             ──> Widened QRS complex & bundle branch block patterns
             ──> Sine-wave rhythm ──> Ventricular Fibrillation / Asystole
  

---

Severe Neonatal Hyperbilirubinemia & Kernicterus

Hyperbilirubinemia is ubiquitous in neonates due to high red blood cell turnover, immature hepatic uridine diphosphate glucuronosyltransferase (UGT1A1) activity, and increased enterohepatic circulation. When unconjugated (indirect), lipid-soluble bilirubin exceeds the albumin-binding capacity, free unconjugated bilirubin crosses the blood-brain barrier.

Neurotoxicity & Target Nuclei

Free bilirubin deposits selectively in lipid-rich central nervous system structures, specifically the globus pallidus, subthalamic nuclei, hippocampus, oculomotor nuclei, and auditory brainstem nuclei.

Acute Bilirubin Encephalopathy (ABE) Clinical Phases

• Phase 1 (Early / Reversible): Mild lethargy, general hypotonia, poor sucking, and a high-pitched cry. Swift intervention can prevent permanent damage.
• Phase 2 (Intermediate): Irritability alternating with lethargy, high-pitched screeching cry, hypertonia of extensor muscles manifested as retrocollis (severe involuntary backward arching of the neck) and opisthotonos (severe backward arching of the entire spine), fever, and stupor.
• Phase 3 (Advanced / Irreversible): Severe retrocollis/opisthotonos, bicycling or seizure-like movements, apnea, inability to feed, deep coma, and death. Survivors develop chronic kernicterus (choreoathetoid cerebral palsy, sensorineural deafness, upward gaze palsy, and dental enamel dysplasia).

Transport Phototherapy Management

• Continuous In-Transit Phototherapy: Severe hyperbilirubinemia approaching exchange levels requires uninterrupted intensive phototherapy. Utilize specialized fiberoptic phototherapy blankets (biliblankets) wrapped directly around the infant's torso inside the transport isolette. When combined with overhead LED phototherapy units, maximum body surface area is irradiated with blue-green light (wavelength 460 to 490 nm), converting toxic (4Z,15Z)-bilirubin into water-soluble photoisomers (lumirubin) excreted in bile and urine without hepatic conjugation.
• Eye Protection: Opaque eye shields (goggles) must be securely applied over the infant's closed eyes to shield retina from irreversible photochemical toxicity. Transport Safety Check: Frequently verify that the eye patch has not slipped down to occlude the neonate's nares or mouth during transport vibration.
• Hydration & Thermal Monitoring: Phototherapy increases insensible fluid losses by 20% to 40% and can induce thermal instability. Maintain rigorous temperature monitoring and titrate intravenous hydration.

Preparation for Double-Volume Exchange Transfusion (DVET)

When total serum bilirubin reaches the exchange-transfusion threshold in the 2022 AAP clinical practice guideline (hour-specific thresholds that depend on gestational age and neurotoxicity risk factors), or whenever an infant shows signs of intermediate or advanced ABE, emergency double-volume exchange transfusion is indicated. The 2022 guideline also defines an escalation-of-care threshold 2 mg/dL below the exchange level, at which intensive phototherapy, urgent labs, and transfer to a center that can perform an exchange begin. In isoimmune hemolytic disease with bilirubin rising despite intensive phototherapy, IVIG (0.5–1 g/kg) may be given.

• Exchange Volume Calculation: Neonatal circulating blood volume is 80 to 90 mL/kg for term infants ($90\text{--}100 \text{ mL/kg}$ for preterms).

$$\text{Double-Volume Exchange Transfusion Volume} = 2 \times \text{Blood Volume} = 160 \text{ to } 180 \text{ mL/kg}$$

• Blood Product Selection: Reconstituted whole blood with a hematocrit of 45% to 50%, composed of type O-negative (or Rh-compatible) packed red blood cells crossmatched against maternal serum, suspended in AB plasma (fresh frozen plasma).
• Transport Team Preparation: Prior to transport departure, insert both an Umbilical Venous Catheter (UVC) and Umbilical Arterial Catheter (UAC). This dual-line setup allows continuous isovolumetric exchange (simultaneously withdrawing blood through the UAC while infusing reconstituted blood through the UVC), eliminating dangerous intracranial and systemic blood pressure spikes associated with older single-line push-pull techniques.